Last updated on April 18, 2014 at 17:24 EDT

Cardiome Announces Publication of Positive Data from an Observational, Retrospective Study of BRINAVESS

October 7, 2013


VANCOUVER, Oct. 7, 2013 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced publication of positive data from an
observational, retrospective study performed at the Skane University
Hospital in Malmö, Sweden. The study included 251 recent-onset atrial
fibrillation (AF) patients who received 355 BRINAVESS(TM) treatments
during the period between January 15, 2011 and April 15, 2013. During
the observation period, 70% of the AF patients treated with BRINAVESS
converted with a median time of 11 minutes. Conversion efficacy was 76%
in patients with AF duration <10 hours. The median time spent in the ER
for patients who converted on BRINAVESS was 6.5 hours. These results
are published in the October 2013 issue of The European Journal of
Cardiovascular Medicine.

“It is exciting to see that patients treated in the clinically critical
first 48 hours after AF onset appear to continue to derive
better-than-expected benefit from BRINAVESS and that they also prefer
this therapy over DC cardioversion,” stated William Hunter, M.D., Chief
Executive Officer of Cardiome Pharma Corp. “The high conversion
efficacy coupled with short hospital stay we believe makes BRINAVESS a
practical option for physicians and patients who value rapid relief
from AF.”

“Skane University Hospital developed a “fast-track” AF program in the
emergency room where patients with short duration AF were promptly
treated with BRINAVESS, which likely contributed to the higher efficacy
seen in this setting compared to the ACT and AVRO clinical trials,”
stated Dr. Steen Juul-Möller, the study’s Principal Investigator and
Cardiome’s Medical Director. “The finding that 75% of successfully
treated BRINAVESS patients remained in normal sinus rhythm after a one
year follow-up period – was an extremely interesting and important
finding that requires further investigation,” added Dr. Juul-Möller.

Patients with recent-onset AF and whom cardioversion was considered were
evaluated for BRINAVESS treatment. Over the period of the study, 251
patients received 355 treatments. In all patients, 70% of BRINAVESS
treatments were successful and 70% of the patients responded at least
once with conversion to sinus rhythm. The conversion rate was higher at
76% among patients with AF duration <10 hours compared to 66% in those
with AF >10 hours (P<0.05). Transient bradycardia and hypotension were
seen in 5 patients (1.4%) occurring within minutes after conversion and
were judged as a response to the change in heart rhythm. No ventricular
tachyarrhythmias, including Torsade-des-Pointes were seen.(1)

Those patients who did not respond to BRINAVESS treatment were
subsequently treated with DC cardioversion. All patients who had
experienced both BRINAVESS and DC cardioversion were given a
questionnaire to assess cardioversion preference and were followed up
for a maximum period of 27 months (BRINAVESS [n = 156]; DC
cardioversion [n=91]). Among those who converted with BRINAVESS, 72%
would prefer this treatment, in patients who did not convert with
BRINAVESS, 61% said they would prefer DC cardioversion if they
experienced a relapse (P<0.001). Furthermore, among BRINAVESS
responders, 78% were satisfied or very satisfied with the treatment.
In the follow up portion of the study, after 12 months, 75% of
BRINAVESS responders were still in sinus rhythm, compared to 45% of
patients that required DC cardioversion (P<0.001).


      1. Juul-Möller, S. Vernakalant in recently developed Atrial
         Fibrillation: How to translate pharmacological trials into
         clinical practice. European Journal of Cardiovascular Medicine.
         Vol. 2, Issue 4. Published online October 4, 2013.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one
marketed product, BRINAVESS(TM) (vernakalant IV), approved in Europe and other territories for the
rapid conversion of recent onset atrial fibrillation to sinus rhythm in

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto
Stock Exchange (COM). For more information, please visit our web site
at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Forward- looking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance
our activities; and any other factors described in detail in our
filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Source: PR Newswire